The United States Food and Drug Administration (FDA) has announced that manufacturers of glucagon-like peptide-1 (GLP-1) receptor agonist medications must update product labels to include warnings about a potential increased risk of a rare, sight-threatening condition. The directive affects popular weight-loss and diabetes treatments, including Ozempic, Wegovy, Mounjaro, Zepbound, and Soliqua.
The condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), occurs when blood flow to the optic nerve is restricted. The FDA stated that NAION can result in sudden, painless vision loss in one eye, which may be permanent. There is currently no known treatment to reverse vision loss caused by this condition.
The decision follows an FDA safety review involving 126 randomised, controlled clinical trials with 134,253 participants. The agency’s analysis identified 15 probable cases of NAION, including 10 among patients using GLP-1 medications and five among those receiving a placebo. No cases were reported in participants taking non-GLP-1 glucose-lowering medications. Novo Nordisk, the manufacturer of Ozempic and Wegovy, stated that current available research does not establish that these medications cause the condition.
The FDA has advised patients who experience symptoms—such as sudden blurring, dimming of vision, or the appearance of blind spots—to contact healthcare professionals immediately. Patients who have already experienced a NAION event are urged to consult their doctors to discuss whether to continue or discontinue their current treatment.
Key facts
- The incidence rate of NAION was 6.4 cases per 100,000 person-years for GLP-1 users versus 3.8 cases for the control group.
- The FDA reviewed 126 clinical trials comprising 134,253 participants to reach their conclusion.
- Symptoms of NAION often appear suddenly and may be first noticed by patients upon waking.
- Individuals with diabetes, high blood pressure, high cholesterol, sleep apnoea, or those over 50 may face a higher risk.
Why it matters
Patients currently prescribed these medications for weight management or type 2 diabetes are advised to monitor their eyesight for any changes. The new labelling is intended to ensure both healthcare providers and users are informed of the potential risks, as these drugs have seen widespread usage for metabolic health and obesity management.
Source: Economic Times, Livemint
Comments